Found 1112 bookmarks
Newest
5 S-Heudelotinone alleviates experimental colitis by shaping the immune system and enhancing the intestinal barrier in a gut microbiota-dependent manner - PubMed
5 S-Heudelotinone alleviates experimental colitis by shaping the immune system and enhancing the intestinal barrier in a gut microbiota-dependent manner - PubMed
Aberrant changes in the gut microbiota are implicated in many diseases, including inflammatory bowel disease (IBD). Gut microbes produce diverse metabolites that can shape the immune system and impact the intestinal barrier integrity, indicating that microbe-mediated modulation may be a promising st …
·pubmed.ncbi.nlm.nih.gov·
5 S-Heudelotinone alleviates experimental colitis by shaping the immune system and enhancing the intestinal barrier in a gut microbiota-dependent manner - PubMed
[The new guideline for gastrointestinal infections] - PubMed
[The new guideline for gastrointestinal infections] - PubMed
Gastrointestinal infections are still responsible for around 60% of the infectious diseases that must be reported in Germany and are probably among the most common gastroenterological diseases. The main therapy for gastrointestinal infections remains oral fluid replacement. The recommendations for …
·pubmed.ncbi.nlm.nih.gov·
[The new guideline for gastrointestinal infections] - PubMed
The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience - PubMed
The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience - PubMed
In the treatment of CDI, we showed that real-world use of fidaxomicin is associated with lower risk of a composite endpoint of treatment failure.
·pubmed.ncbi.nlm.nih.gov·
The clinical effectiveness of Fidaxomicin compared to Vancomycin in the treatment of Clostridioides difficile infection, a single center real-world experience - PubMed
Shortened Treatment Regimen Resolves C difficile Infection
Shortened Treatment Regimen Resolves C difficile Infection
Antimicrobial stewardship to reduce multidrug resistance and opportunistic Clostridioides difficile infection (CDI) could also guide shorter treatment.
·news.google.com·
Shortened Treatment Regimen Resolves C difficile Infection
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Clostridium Difficile Infections...
·news.google.com·
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection - PubMed
Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection - PubMed
Clostridioides difficile (C. difficile) is one of the leading causes of healthcare-associated infections worldwide. The increasing incidence of strains resistant to currently available therapies highlights the need for alternative treatment options with a novel mode of action. Oxazolid …
·pubmed.ncbi.nlm.nih.gov·
Discovery and Structure-Activity Relationship of Cadazolid: A First-In-Class Quinoxolidinone Antibiotic for the Treatment of Clostridioides difficile Infection - PubMed
Living With C diff: Witnessing and Participating in an Evolution of Awareness, Medical Care
Living With C diff: Witnessing and Participating in an Evolution of Awareness, Medical Care
Dennis Petragnani has battled gastrointestinal issues for years, and he shares what he sees as the transformation of change in the public and medical community talking about C diff and therapies around it, and the kinship with people he has met through the Peggy Lillis Foundation.
·news.google.com·
Living With C diff: Witnessing and Participating in an Evolution of Awareness, Medical Care
Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies - PubMed
Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies - PubMed
Clostridioides difficile is a toxin-producing bacteria that is a main cause of antibiotic-associated diarrhea. Clostridioides difficile infections (CDI) are associated with disruptions within the gastrointestinal (GI) microbiota which can be further exacerbated by CDI-targeted antibiot …
·pubmed.ncbi.nlm.nih.gov·
Breaking the Cycle of Recurrent Clostridioides difficile Infections: A Narrative Review Exploring Current and Novel Therapeutic Strategies - PubMed
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Pune, Feb. 19, 2024 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, the global Clostridium Difficile Infections Treatment Market is expected to clock US$ 1,727.1 million by 2031 and to grow at a CAGR of 6.8% during the forecast period. The global Clostridium difficile Infections (CDI) Treatment Market is witnessing significant growth, driven by the rising incidence of CDI, increasing antibiotic resistance, and the demand for effective treatment options to com
·news.google.com·
Clostridium Difficile Infections Treatment Market is set to Reach US$ 1,727.1 million at a CAGR of 6.8% from the forecast period 2023 to 2031 | Growth Plus Reports
Fighting against Clostridioides difficile infection: Current medications - PubMed
Fighting against Clostridioides difficile infection: Current medications - PubMed
Clostridioides difficile (formerly Clostridium difficile) has been regarded as an "urgent threat" and a significant global health problem, as life-threatening diarrhea and refractory recurrence are common in patients with C. difficile infection (CDI). Unfortunately, the available anti-CDI drugs are …
·pubmed.ncbi.nlm.nih.gov·
Fighting against Clostridioides difficile infection: Current medications - PubMed
Clostridioides Difficile: A Concise Review of Best Practices and Updates - PubMed
Clostridioides Difficile: A Concise Review of Best Practices and Updates - PubMed
Clostridioides difficile infection (CDI) is one of the most common and severe nosocomial infections worldwide. It can also affect healthy individuals in the community. The incidence of CDI has been on the rise globally for the past decade, necessitating a proactive approach to combat its spread; new …
·pubmed.ncbi.nlm.nih.gov·
Clostridioides Difficile: A Concise Review of Best Practices and Updates - PubMed
Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD - PubMed
Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD - PubMed
Vancomycin and metronidazole are commonly used treatments for Clostridioides difficile infection (CDI). However, these antibiotics have been associated with high levels of relapse in patients. Fidaxomicin is a new treatment for CDI that is described as a narrow spectrum antibiotic that is min …
·pubmed.ncbi.nlm.nih.gov·
Comparison of fidaxomicin, thuricin CD, vancomycin and nisin highlights the narrow spectrum nature of thuricin CD - PubMed
Validation of clinical risk tools for recurrent Clostridioides difficile infection - PubMed
Validation of clinical risk tools for recurrent Clostridioides difficile infection - PubMed
All tools performed poorly for predicting recurrent C. difficile infection (AUROC range: 0.488-0.564), especially among patients with a prior history of infection (AUROC range: 0.436-0.591). Future studies may benefit from considering novel biomarkers and/or higher-dimensional models that cou …
·pubmed.ncbi.nlm.nih.gov·
Validation of clinical risk tools for recurrent Clostridioides difficile infection - PubMed
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection - PubMed
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection - PubMed
Clostridioides difficile infection causes pathology that ranges in severity from diarrhea to pseudomembranous colitis. Toxin A and Toxin B are the two primary virulence factors secreted by C. difficile that drive disease severity. The toxins damage intestinal epithelial cells leading to a loss of ba …
·pubmed.ncbi.nlm.nih.gov·
Monoclonal antibody-mediated neutralization of Clostridioides difficile toxin does not diminish induction of the protective innate immune response to infection - PubMed
Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat? - PubMed
Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat? - PubMed
Delayed CDI treatment was associated with disease progression and could represent an important antimicrobial stewardship measure with future evaluation.
·pubmed.ncbi.nlm.nih.gov·
Impact of time to treatment in first occurrence, non-severe Clostridioides difficile infection for elderly patients: are we waiting too long to treat? - PubMed
Incidence, Clinical Characteristics, and Outcomes of Clostridium difficile Infection in a Tertiary Care Center in Bahrain - PubMed
Incidence, Clinical Characteristics, and Outcomes of Clostridium difficile Infection in a Tertiary Care Center in Bahrain - PubMed
Background Clostridioides difficile infection (CDI) represents a significant healthcare challenge associated with antibiotic use and healthcare settings. While healthcare facility-onset CDI (HO-CDI) rates have been extensively studied, the incidence and risk factors of CDI in various settings …
·pubmed.ncbi.nlm.nih.gov·
Incidence, Clinical Characteristics, and Outcomes of Clostridium difficile Infection in a Tertiary Care Center in Bahrain - PubMed
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
The dipeptide D-Ala-D-Ala is an essential component of peptidoglycan and the target of vancomycin. Most Clostridioides difficile strains possess the vanG operon responsible for the synthesis of D-Ala-D-Ser, which can replace D-Ala-D-Ala in peptidoglycan. The C. difficile vanG operon is regulated by …
·pubmed.ncbi.nlm.nih.gov·
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment - PubMed
Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment - PubMed
Up to 25% of patients recovering from antibiotic-treated Clostridioides difficile infection (CDI) develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS). For patients with persistent symptoms following infection, a clinical dilemma arises as to whether to provid …
·pubmed.ncbi.nlm.nih.gov·
Post-infectious ibs following Clostridioides difficile infection; role of microbiota and implications for treatment - PubMed
Scutellaria baicalensis Georgi alleviates Clostridium difficile associated diarrhea and its modulatory effects on the gut microbiota - PubMed
Scutellaria baicalensis Georgi alleviates Clostridium difficile associated diarrhea and its modulatory effects on the gut microbiota - PubMed
The growing incidence of Clostridium difficile associated diarrhea (CDAD) underscores the urgency for potent treatments. This research delves into the therapeutic potential of Scutellaria baicalensis Georgi (Lamiaceae) root (SR) in addressing CDAD and its influence on gut microbiota. Using a CDAD mo …
·pubmed.ncbi.nlm.nih.gov·
Scutellaria baicalensis Georgi alleviates Clostridium difficile associated diarrhea and its modulatory effects on the gut microbiota - PubMed
Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection - PubMed
Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection - PubMed
Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our Clostridioides difficile infection (CDI) clinic did not require further treatment. The overall 60-day CDI recurrence rate was 16.9% (11/65). CDI man …
·pubmed.ncbi.nlm.nih.gov·
Management and Outcomes of Patients at a Specialty Clinic for Clostridioides difficile Infection - PubMed
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
The dipeptide D-Ala-D-Ala is an essential component of peptidoglycan and the target of vancomycin. Most Clostridioides difficile strains possess the vanG operon responsible for the synthesis of D-Ala-D-Ser, which can replace D-Ala-D-Ala in peptidoglycan. The C. difficile vanG operon is regulated by …
·pubmed.ncbi.nlm.nih.gov·
Histidine kinase-mediated cross-regulation of the vancomycin-resistance operon in Clostridioides difficile - PubMed
Enhancing Clostridium difficile Treatment and Prevention Efforts
Enhancing Clostridium difficile Treatment and Prevention Efforts
Insights from Dr. Md Zahidul Alam on treatments and prevention strategies for C difficile infection (CDI), supported by the CDC's recent study on CDI management in healthcare settings.
·news.google.com·
Enhancing Clostridium difficile Treatment and Prevention Efforts
C. diff in 2024: New Treatments For a Stubborn Problem
C. diff in 2024: New Treatments For a Stubborn Problem
The key to understanding and effectively treating Clostridioides difficile infection is noting its two phases: the vegetative state that releases toxins and causes ...
·pharmacypracticenews.com·
C. diff in 2024: New Treatments For a Stubborn Problem